<aside> 📢
Embargo released: 25 August 2025.
</aside>
A pioneering collaboration between Diag-Nose.io and Human Health has secured $3M in funding under the Australian Government’s Cooperative Research Centres Projects (CRC-P) program to accelerate RhinoMAP - an AI-enabled platform set to transform how respiratory diseases like asthma, sinusitis, and COPD are monitored and treated.
Despite recent breakthroughs in respiratory treatments, a recent Australian study found that 40%-50% patients do not achieve the expected results. This CRCP project aims to close this gap, reducing trial-and-error treatment plans and unnecessary healthcare costs.
“Current respiratory tools only tell half the story.” says Eldin Rostom, CEO and Co-Founder of Diag-Nose.io.
“New drugs such as biologics are life-changing but are expensive and slow to show results, which often lead to clinical uncertainty, lower patient adherence, and suboptimal use of healthcare resources.”
“Our platform, RhinoMAP, is like a radar for the respiratory system. It reveals whether inflammation is escalating, stable, or resolving to help clinicians course-correct or stay the path with confidence, guided by the disease biology itself.”
The platform uses protein biomarkers from a nasal fluid sample and combines them with patient-reported data to deliver a real-time picture of airway inflammation. Its AI algorithms will enable clinicians to track whether high-cost treatments like biologics are working before current tools would show results.
The ABEL Microsampler: an Australian Innovation - a minimally-invasive nasal sampling device that will be used during the study to develop the biomarker platform.
The national collaboration is backed by a total project value of $8.4 million, including partner cash and in-kind contributions. The initiative brings together leading experts from Monash University, Mater Research, ENT Clinic Melbourne, Manse Medical, and Invetech alongside trailblazing startups such as Diag-Nose.io and Human Health.